Drugs / RG547
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00400296 | May 2005 → Nov 2008 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG547 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00400296 ↗ |
| Known as | R 547 | ChEMBL registry synonym — accepted as the source's own label CHEMBL384304 ↗ |
| Known as | RO4584820 | ChEMBL registry synonym — accepted as the source's own label CHEMBL384304 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase 2 inhibitor” CHEMBL384304 ↗2“Cyclin-dependent kinase 4 inhibitor” CHEMBL384304 ↗ “Cyclin-dependent kinase 1 inhibitor” CHEMBL384304 ↗ |
| Modality | Small molecule | — CHEMBL384304 ↗ |
| Route | Intravenous | “Administered as an Intravenous Infusion” NCT00400296 ↗ |
| Target | CDK1 | “Cyclin-dependent kinase 1 inhibitor” CHEMBL384304 ↗ |
| Target | CDK2 | “Cyclin-dependent kinase 2 inhibitor” CHEMBL384304 ↗ |
| Target | CDK4 | “Cyclin-dependent kinase 4 inhibitor” CHEMBL384304 ↗ |